TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Guest Editorial: Omics Checklist Done, Now Create Business Model For Tests February 7, 2013
TCL Archive FDA Revokes Avastin’s Accelerated Approval In Metastatic Breast Cancer Indication November 18, 2011
TCL Archive OSU Continues As comprehensive Center; City Of Hope BMT Program Wins 5-Year Grant. July 14, 2000
